ATE252078T1 - Carbonsäuren und carbonsäureisostere von n- heterocyclischen verbindungen - Google Patents

Carbonsäuren und carbonsäureisostere von n- heterocyclischen verbindungen

Info

Publication number
ATE252078T1
ATE252078T1 AT99961930T AT99961930T ATE252078T1 AT E252078 T1 ATE252078 T1 AT E252078T1 AT 99961930 T AT99961930 T AT 99961930T AT 99961930 T AT99961930 T AT 99961930T AT E252078 T1 ATE252078 T1 AT E252078T1
Authority
AT
Austria
Prior art keywords
treating
carboxylic acids
eisosters
heterocyclic compounds
carboxic acid
Prior art date
Application number
AT99961930T
Other languages
English (en)
Inventor
Gregory S Hamilton
Mark H Norman
Yong-Qian Wu
Original Assignee
Guilford Pharm Inc
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharm Inc, Amgen Inc filed Critical Guilford Pharm Inc
Application granted granted Critical
Publication of ATE252078T1 publication Critical patent/ATE252078T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
AT99961930T 1998-12-03 1999-12-03 Carbonsäuren und carbonsäureisostere von n- heterocyclischen verbindungen ATE252078T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20423798A 1998-12-03 1998-12-03
US09/453,571 US6331537B1 (en) 1998-06-03 1999-12-02 Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
PCT/US1999/028663 WO2000032588A2 (en) 1998-12-03 1999-12-03 Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds

Publications (1)

Publication Number Publication Date
ATE252078T1 true ATE252078T1 (de) 2003-11-15

Family

ID=26899306

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99961930T ATE252078T1 (de) 1998-12-03 1999-12-03 Carbonsäuren und carbonsäureisostere von n- heterocyclischen verbindungen

Country Status (20)

Country Link
US (2) US6331537B1 (de)
EP (1) EP1135370B1 (de)
KR (1) KR20010086080A (de)
CN (1) CN1213026C (de)
AT (1) ATE252078T1 (de)
AU (1) AU767468B2 (de)
BG (1) BG105643A (de)
BR (1) BR9916461A (de)
CA (1) CA2353460C (de)
CZ (1) CZ20011971A3 (de)
DE (1) DE69912151T2 (de)
EA (1) EA003926B1 (de)
HU (1) HUP0105027A3 (de)
IL (1) IL143392A0 (de)
MX (1) MXPA01005549A (de)
NO (1) NO318909B1 (de)
NZ (1) NZ511673A (de)
PL (1) PL348715A1 (de)
SK (1) SK7442001A3 (de)
WO (1) WO2000032588A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US6274602B1 (en) * 1998-06-03 2001-08-14 Gpi Nil Holdings, Inc. Heterocyclic thioester and ketone hair growth compositions and uses
US20010049381A1 (en) * 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
WO1999014998A2 (en) * 1997-09-24 1999-04-01 Amgen Inc. Method for preventing and treating hearing loss using sensorineurotrophic compounds
CN1382140A (zh) 1999-07-09 2002-11-27 奥索-麦克尼尔药品公司 具有神经营养活性的吡咯烷和哌啶、以及含有它们的相关组合物
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
US6809093B2 (en) 2000-10-17 2004-10-26 H. Lee Moffitt Cancer & Research Institute, Inc. 2-substituted heterocyclic compounds
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
US6916850B2 (en) 2001-05-03 2005-07-12 Galileo Pharmaceuticals, Inc. Pyruvate derivatives
WO2002096420A2 (en) * 2001-05-29 2002-12-05 Guilford Pharmaceuticals Inc. Method for treating nerve injury caused by surgery
AUPR879201A0 (en) * 2001-11-09 2001-12-06 Cochlear Limited Subthreshold stimulation of a cochlea
US20050171579A1 (en) * 2001-11-09 2005-08-04 Claudia Tasche Stimulating device
US20100030301A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Electrical stimulation for modulation of neural plasticity
US20100030130A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Pharmaceutical intervention for modulation of neural plasticity
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
MXPA05001202A (es) 2002-07-29 2005-11-23 Hawaii Biotech Inc Analogos carotenoides estructurales para la inhibicion y mejora de la enfermedad.
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
AU2003259846A1 (en) * 2002-08-16 2004-03-03 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
RU2005113247A (ru) * 2002-10-03 2006-01-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Производные пиперазина и пиперидина для лечения неврологических заболеваний
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
WO2005102356A1 (en) * 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
WO2005122887A2 (en) 2004-06-15 2005-12-29 Cochlear Americas Automatic determination of the threshold of an evoked neural response
US20060116423A1 (en) * 2004-10-18 2006-06-01 Dash Pramod K Methods and compositions for treatment of central nervous system injury with isothiocyanates
AU2005311826A1 (en) * 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as PPAR active compounds
MX2007011453A (es) 2005-04-22 2008-02-12 Alantos Pharmaceuticals Holding Inc Inhibidores de la dipeptidil peptidasa-iv.
WO2006138187A1 (en) * 2005-06-13 2006-12-28 Yong-Qian Wu Enhanced tissue penetration prodrugs
CA2621474A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1,3-disubstituted indole derivatives for use as ppar modulators
DE102005050377A1 (de) * 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
NZ601866A (en) 2007-06-29 2013-12-20 Acucela Inc Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
MX2010003667A (es) 2007-10-05 2010-09-28 Acucela Inc Compuestos alcoxi para el tratamiento de enfermedades.
AR070950A1 (es) 2007-11-01 2010-05-19 Acucela Inc Compuestos derivados de amina, composiciones farmaceuticas de ellos, compuestos inhibidores de produccion de 11-cis-retinol y metodos para tratar enfermedades y trastornos oftalmicos
JP5657524B2 (ja) 2008-04-24 2015-01-21 エフツージー リミテッド ピロール抗真菌剤
EP2309858A4 (de) 2008-07-31 2011-09-14 Dekel Pharmaceuticals Ltd Zusammensetzungen und verfahren zur behandlung von entzündungserkrankungen
BRPI0919920A2 (pt) 2008-10-22 2016-02-16 Acucela Inc compostos para tratamento de doenças e desordens oftálmicas
US20100317711A1 (en) * 2008-12-17 2010-12-16 Gliamed, Inc. Stem-like cells and method for reprogramming adult mammalian somatic cells
ES2897527T3 (es) * 2009-07-02 2022-03-01 Acucela Inc Farmacología de moduladores del ciclo visual
US9981018B2 (en) * 2010-06-08 2018-05-29 The Cleveland Clinic Foundation Compositions and methods for modulating toll-like receptor 2 activation
EP2804605A4 (de) 2012-01-20 2015-07-08 Acucela Inc Substituierte heterocyclische verbindungen zur behandlung von krankheiten
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
MX376108B (es) 2012-12-20 2025-03-07 Tempest Therapeutics Inc Compuestos de triazolona y usos de los mismos.
AU2014315151A1 (en) 2013-09-06 2016-03-03 Inception 2, Inc. Triazolone compounds and uses thereof
WO2015112902A2 (en) * 2014-01-23 2015-07-30 Sova Pharmaceuticals, Inc. CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN
PL3221308T3 (pl) 2014-11-21 2019-03-29 F2G Limited Środki przeciwgrzybicze
US10285977B2 (en) * 2015-08-13 2019-05-14 David Weinstein Consulting, Inc. Compositions and methods for treating alopecia
ES2828434T3 (es) * 2015-08-13 2021-05-26 River Town Therapeutics Inc AT175, minoxidil y ciclosporina A para el tratamiento de la alopecia
EP3432987A4 (de) * 2016-03-21 2019-12-25 David Weinstein Verfahren zur wundheilung und narbenverhinderung
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US10709686B2 (en) * 2018-03-20 2020-07-14 David Weinstein Consulting, Inc. Methods for treating pulmonary fibrosis
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
US20220265668A1 (en) * 2019-07-25 2022-08-25 Sensorion Treatment and/or prevention of lesions in the central auditory nervous system

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA794723B (en) 1978-09-11 1980-08-27 Univ Miami Anti-hypertensive agents
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
IT1148775B (it) 1980-02-29 1986-12-03 Attilio Pronzati Bastoncini da sci dotati di rotelle intercambiabili
US4692458A (en) 1980-03-05 1987-09-08 University Of Miami Anti-hypertensive agents
US4734420A (en) 1980-03-05 1988-03-29 University Of Miami Anti-hypertensive agents
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
EP0048159A3 (de) 1980-09-17 1982-05-12 University Of Miami Carboxyalkyl-Peptide und Thioäther und Äther von Peptiden als antihypertensive Mittel
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
LU88621I2 (fr) 1980-10-23 1995-09-01 Schering Corp Sandopril
US5348944A (en) 1980-10-23 1994-09-20 Schering Corporation Carboxyalkyl dipeptides
ZA826022B (en) 1981-08-21 1983-08-31 Univ Miami Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides
US4766110A (en) * 1981-08-21 1988-08-23 Ryan James W Novel complex amido and imido derivatives of carboxyalkyl peptides
US4431644A (en) 1982-03-08 1984-02-14 Schering Corporation Antihypertensive agents
DE3360065D1 (en) 1982-03-08 1985-03-28 Schering Corp Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
WO1985004577A1 (en) 1984-04-06 1985-10-24 Gail Sansone Bazzano Compositions used for hair growth
US4595766A (en) 1984-10-26 1986-06-17 Ciba-Geigy Corporation Process for the preparation of an indoline carboxylic acid
DE3508251A1 (de) 1985-03-08 1986-09-11 Merck Patent Gmbh, 6100 Darmstadt Dipeptide
CN86101850A (zh) 1985-03-22 1987-02-04 森得克斯(美国)有限公司 N，n′-二烷基胍基二肽的制造方法与用途
US5714510A (en) 1985-07-18 1998-02-03 Proctor; Peter H. Topical proxyl composition and method
US5472687A (en) 1985-07-18 1995-12-05 Proctor; Peter H. Topical pyridine N-oxides
WO1988000040A1 (en) 1986-07-02 1988-01-14 American Health Products Corporation Topical hair growing composition and kit
US5214034A (en) 1986-09-26 1993-05-25 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system containing the same
DE3636278A1 (de) 1986-10-24 1988-05-05 Hoechst Ag Herbizide mittel auf der basis von cyclischen (alpha)-iminocarbon-saeureaniliden sowie neue (alpha)-iminocarbonsaeureanilide und verfahren zu ihrer herstellung
IT1206078B (it) 1987-06-03 1989-04-14 Polifarma Spa Procedimento per la produzione di acido 3-indolpiruvico e suoi derivati loro uso farmaceutico
WO1989006234A1 (en) 1987-12-28 1989-07-13 Bazzano Gail S N,n-substituted amines and use thereof in hair growth promotion
US5187156A (en) 1988-03-16 1993-02-16 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
US5232923A (en) 1988-03-18 1993-08-03 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives and pharmaceutical preparations containing same
US5274097A (en) 1988-04-19 1993-12-28 Bayer Aktiengesellschaft 1,3-disubstituted pyrrolidines
IL90872A0 (en) 1988-07-08 1990-02-09 Smithkline Beckman Corp Retroviral protease binding peptides
US5002962A (en) 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5166317A (en) 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
EP0378318A1 (de) 1989-01-11 1990-07-18 Merck & Co. Inc. Verfahren zur Herstellung von FK-506 sowie Tricarbonylzwischenprodukten
US5359138A (en) 1989-04-15 1994-10-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Poststatin and related compounds or salts thereof
US5164525A (en) 1989-06-30 1992-11-17 Merck & Co., Inc. Synthetic process for fk-506 type macrolide intermediates
US5128483A (en) 1989-07-19 1992-07-07 American Cyanamid Company Dibromovinyl and acetylene-1-pyrrolidinecarboxylic acid intermediates
US5215969A (en) 1989-08-11 1993-06-01 Hahnemann University Dopaminergic neurotrophic factor for treatment of Parkinson's disease
US5703088A (en) 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
EP0443983B1 (de) 1990-02-19 1996-02-28 Ciba-Geigy Ag Acylverbindungen
US5115098A (en) 1990-02-28 1992-05-19 President And Fellows Of Harvard College End-blocked peptides inhibiting binding capacity of gp120
JPH04211648A (ja) 1990-07-27 1992-08-03 Nippon Kayaku Co Ltd ケト酸アミド誘導体
DE4015255A1 (de) 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
US5504197A (en) 1990-06-20 1996-04-02 The Salk Institute For Biological Studies DNA encoding neurotrophic growth factors
US5192773A (en) 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
ATE154230T1 (de) 1990-08-14 1997-06-15 Kenneth M Hallam Haarwuchsmittel
WO1992004370A1 (en) 1990-08-29 1992-03-19 Vertex Pharmaceuticals Incorporated Modified di- and tripeptidyl immunosuppressive compounds
GB2247456A (en) 1990-09-03 1992-03-04 Fujisawa Pharmaceutical Co Tetrahydropyrane compounds, a process for their production and a pharmaceutical composition containing the same
JPH04124198A (ja) 1990-09-12 1992-04-24 Sumitomo Pharmaceut Co Ltd 神経栄養ペプチド誘導体
DE69118826T2 (de) 1990-11-27 1996-11-14 Fuji Photo Film Co Ltd Propenamidderivate, deren Polymere, Copolymere und deren Verwendung
AU9049391A (en) 1990-12-20 1992-07-22 Warner-Lambert Company 2-acylamido derivatives of 3,4-dihydro-3-oxo-quinoxaline having pharmaceutical activity
WO1992011850A2 (en) 1990-12-28 1992-07-23 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
FR2671082B1 (fr) 1990-12-28 1993-04-16 Oreal Agent a plusieurs composants ou kit de preparation de la forme sulfo-conjuguee de composes pyrimidino- ou triazino-n-oxyde et procede de mise en óoeuvre.
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5147877A (en) 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
HUT70259A (en) 1991-05-08 1995-09-28 Vertex Pharma Rfkbp: a novel isomerase and papamycin/fk506 binding protein
DE69229782T2 (de) 1991-05-09 2000-04-27 Vertex Pharmaceuticals Inc., Cambridge Neue immunsuppressive verbindungen
US5620971A (en) 1991-05-09 1997-04-15 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
MX9202466A (es) 1991-05-24 1994-06-30 Vertex Pharma Compuestos inmunosupresores novedosos.
FR2677884B1 (fr) 1991-06-20 1993-07-09 Oreal Composition pour freiner la chute des cheveux a base de pyrimidines n-oxyde trisubstitues ou leurs derives sulfoconjugues, nouveaux composes pyrimidines n-oxyde ou leurs derives sulfoconjugues.
JPH05194235A (ja) 1991-07-25 1993-08-03 Tanabe Seiyaku Co Ltd 中枢性カルシウム拮抗剤
JPH05178824A (ja) 1991-08-05 1993-07-20 Takeda Chem Ind Ltd アスパラギン誘導体およびその用途
US5604294A (en) 1991-09-05 1997-02-18 Luly; Jay R. Macrocyclic immunomodulators
WO1993013066A1 (en) 1991-12-20 1993-07-08 Syntex (U.S.A.) Inc. Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
GB9200245D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
AU3477093A (en) 1992-01-27 1993-09-01 Merck & Co., Inc. 17beta -hydroxybenzoyl-4-aza-5alpha-androst-1-en-3-ones useful to treat baldness
WO1993018736A1 (fr) 1992-03-19 1993-09-30 Armand Pardo Compositions cosmetiques capillaires destinees aux traitements contre la chute des cheveux
CA2091194A1 (en) 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
US5342942A (en) 1992-06-09 1994-08-30 Warner-Lambert Company Pyrazoloquinazolone derivatives as neurotrophic agents
GB9216329D0 (en) 1992-07-31 1992-09-16 Erba Carlo Spa 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives
DE4228455A1 (de) 1992-08-26 1994-09-15 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Thiolen und/oder Thiolderivaten
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
NZ314207A (en) 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
KR0165704B1 (ko) 1992-11-20 1999-01-15 미즈노 마사루 프롤릴 엔도펩티다아제 억제 활성을 갖는 화합물 및 그 약학적 용도
WO1994013629A1 (en) 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
US5411991A (en) 1992-12-22 1995-05-02 Shander; Douglas Method of reducing hair growth employing sulfhydryl active compounds
US5646167A (en) 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5264619B1 (en) 1993-01-15 1996-05-14 Cosmos Pharm Corp Anti-androgenic cyclo and bicyclo alkenes
EP0610744B1 (de) 1993-02-09 1998-11-04 Bayer Corporation Sulfonamidaminomethylenderivate als Immunsuppressiva
WO1994021253A1 (en) 1993-03-17 1994-09-29 Abbott Laboratories Substituted aliphatic amine-containing macrocyclic immunomodulators
JP3599287B2 (ja) 1993-04-28 2004-12-08 三菱化学株式会社 スルホンアミド誘導体
US5319098A (en) * 1993-05-18 1994-06-07 Celgene Corporation Process for the stereoselective preparation of L-alanyl-L-proline
US5846981A (en) 1993-05-28 1998-12-08 Gpi Nil Holdings Inc. Inhibitors of rotamase enzyme activity
US5798355A (en) 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
FI960165L (fi) 1993-07-16 1996-01-26 Univ Leland Stanford Junior Säädetty apoptoosi
IT1270882B (it) 1993-10-05 1997-05-13 Isagro Srl Oligopeptidi ad attivita' fungicida
CA2152822A1 (en) 1993-11-04 1995-05-11 William R. Baker Cyclobutane derivatives as inhibitors of squalene synthetase and protein farnesyltransferase
ATE178795T1 (de) 1993-11-04 1999-04-15 Merck & Co Inc 7-substituierte-4-aza-steroid-derivate als 5- alpha-reductase-hemmer
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5612350A (en) 1993-11-30 1997-03-18 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements
US5744485A (en) 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5898029A (en) 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
AU2825295A (en) 1994-06-13 1996-01-05 Arcturus Pharmaceutical Corporation Method for the treatment, prevention or minimization of hair loss
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5856116A (en) 1994-06-17 1999-01-05 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1 beta converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
DE4425950A1 (de) 1994-07-21 1996-01-25 Bayer Ag Verwendung von Sulfonylbenzyl-substituierten Imidazolen, Imidazopyridinen und Benzimidazolen
ES2245781T3 (es) * 1994-08-18 2006-01-16 Ariad Gene Therapeutics, Inc. Nuevos agentes de multimerizacion.
WO1996006846A1 (es) 1994-09-01 1996-03-07 Universidad Complutense De Madrid Nuevos derivados de arilpiperazinas
US5543423A (en) 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
IL115685A (en) 1994-11-16 2000-08-31 Vertex Pharma Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
US5621108A (en) 1994-12-05 1997-04-15 Trustees Of The University Of Pennsylvania Processes and intermediates for preparing macrocycles
US5863902A (en) 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5726184A (en) 1995-05-19 1998-03-10 Vertex Pharmaceuticals Incorporated Tetralin compounds with improved MDR activity
US5859031A (en) 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5614547A (en) 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US5696135A (en) 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US6291510B1 (en) * 1995-06-07 2001-09-18 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US6037370A (en) 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5801197A (en) 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5646180A (en) 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
AU1463997A (en) 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
WO1997031898A1 (en) * 1996-02-28 1997-09-04 Ariad Gene Therapeutics, Inc. Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains
US5717092A (en) 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity
US5905076A (en) 1996-04-10 1999-05-18 National Research Council Of Canada 6-substituted amino-4-oxa-1-azabicyclo 3,2,0! heptan-7-one derivatives as cysteine protease inhibitors
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
EP0912550A1 (de) 1996-06-25 1999-05-06 Smithkline Beecham Plc Sulfonamide derivatives als 5ht7 rezeptor antagoniste
TW397809B (en) 1996-08-09 2000-07-11 Takeda Chemical Industries Ltd Dimethylpropanediol compounds
HUP0000505A3 (en) 1996-08-28 2001-12-28 Procter & Gamble Saturated 7-9 membered heterocyclic n-hydroxycarboxamide derivatives and pharmaceutical compositions containing them
US5786378A (en) 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US5801187A (en) * 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US5780484A (en) 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5811434A (en) 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
WO1998022432A1 (en) 1996-11-18 1998-05-28 Yamanouchi Pharmaceutical Co., Ltd. Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same
JP4274584B2 (ja) 1996-12-06 2009-06-10 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−１β変換酵素のインヒビター
US5874449A (en) 1996-12-31 1999-02-23 Gpi Nil Holdings, Inc. N-linked sulfonamides of heterocyclic thioesters
US5935989A (en) 1996-12-31 1999-08-10 Gpi Nil Holdings Inc. N-linked ureas and carbamates of heterocyclic thioesters
US5721256A (en) 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
US5846979A (en) * 1997-02-28 1998-12-08 Gpi Nil Holdings, Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
US5945441A (en) * 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
CA2300134A1 (en) 1997-08-29 1999-03-04 Vertex Pharmaceuticals Incorporated Compounds possessing neuronal activity
WO1999014998A2 (en) * 1997-09-24 1999-04-01 Amgen Inc. Method for preventing and treating hearing loss using sensorineurotrophic compounds
GB9804426D0 (en) 1998-03-02 1998-04-29 Pfizer Ltd Heterocycles
CN100351230C (zh) * 1998-06-03 2007-11-28 Gpinil控股公司 N－杂环化合物的羧酸和羧酸电子等排物
US6284779B1 (en) * 1999-02-03 2001-09-04 Schering Aktiiengesellschaft Heteroaromatic compounds

Also Published As

Publication number Publication date
WO2000032588A2 (en) 2000-06-08
WO2000032588A3 (en) 2001-02-22
AU767468B2 (en) 2003-11-13
HUP0105027A3 (en) 2002-10-28
EP1135370B1 (de) 2003-10-15
EA003926B1 (ru) 2003-10-30
NZ511673A (en) 2004-03-26
CN1330634A (zh) 2002-01-09
SK7442001A3 (en) 2001-12-03
CZ20011971A3 (cs) 2001-09-12
US6331537B1 (en) 2001-12-18
US7153883B2 (en) 2006-12-26
HUP0105027A2 (hu) 2002-05-29
BG105643A (en) 2002-02-28
AU1841300A (en) 2000-06-19
EP1135370A2 (de) 2001-09-26
KR20010086080A (ko) 2001-09-07
CN1213026C (zh) 2005-08-03
PL348715A1 (en) 2002-06-03
MXPA01005549A (es) 2003-07-14
NO20012765L (no) 2001-07-20
NO20012765D0 (no) 2001-06-05
DE69912151T2 (de) 2004-07-08
CA2353460C (en) 2009-11-10
BR9916461A (pt) 2001-09-04
IL143392A0 (en) 2002-04-21
EA200100570A1 (ru) 2001-12-24
CA2353460A1 (en) 2000-06-08
US20030186961A1 (en) 2003-10-02
DE69912151D1 (de) 2003-11-20
NO318909B1 (no) 2005-05-23

Similar Documents

Publication Publication Date Title
DE69912151D1 (de) Carbonsäuren und carbonsäureisostere von n-heterocyclischen verbindungen
BG105012A (en) N-linked sulphonamides of n-heterocyclic carboxylic acids or carboxylic isosteres
ATE319712T1 (de) Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
RU93049265A (ru) Производные декагидроизохинолинов, способ получения, фармацевтическая композиция
EA200500007A1 (ru) Пролекарства возбуждающих аминокислот
ATE302194T1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
RU93058531A (ru) Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
BR9507073A (pt) Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto
DE69837564D1 (de) Azaheterozyklischederivate zur behandlung von haarausfall und neurologischer krankheiten
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
DE60135904D1 (de) Arzneien zur behandlung von nervenerkrankungen
WO1999062879A8 (en) Ureas and carbamates of n-heterocyclic carboxylic acids and carboxylic acid isosteres
BR9815919A (pt) Compostos aza heterocìclicos usados para tratar distúrbios neurológicos e perda de cabelo
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
NO20052153L (no) Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.
ATE230263T1 (de) At1 rezeptor antagonist zur anregung von apoptosis
DE602004014115D1 (de) Neue amidderivate von 2,2,3,3-tetramethylcyclopropancarbonsäure
TW200600512A (en) Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds
DE50000562D1 (de) Mittel zur behandlung von pigmentierungsstörungen
EA201001895A1 (ru) Пролекарства возбуждающих аминокислот

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties